Regulation of AKT Activity by Inhibition of the Pleckstrin Homology Domain-PtdIns(3,4,5)P3 Interaction Using Flavonoids
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The serine-threonine kinase AKT plays a pivotal role in tumor progression and is frequently overactivated in cancer cells; this protein is therefore a critical therapeutic target for cancer intervention. We aimed to identify small molecule inhibitors of the pleckstrin homology (PH) domain of AKT to disrupt binding of phosphatidylinositol-3,4,5-trisphosphate (PIP3), thereby downregulating AKT activity. Liposome pulldown assays coupled with fluorescence spectrometry were used to screen flavonoids for inhibition of the AKT PH-PIP3 interaction. Western blotting was used to determine the effects of the inhibitors on AKT activation in cancer cells, and in silico docking was used for structural analysis and optimization of inhibitor structure. Several flavonoids showing up to 50% inhibition of the AKT PH-PIP3 interaction decreased the level of AKT activation at the cellular level. In addition, the modified flavonoid showed increased inhibitory effects and the approach would be applied to develop anticancer drug candidates. In this study, we provide a rationale for targeting the lipidbinding domain of AKT, rather than the catalytic kinase domain, in anticancer drug development.
Abstract
The serine-threonine kinase AKT plays a pivotal role in tumor progression and is frequently overactivated in cancer cells; this protein is therefore a critical therapeutic target for cancer intervention. We aimed to identify small molecule inhibitors of the pleckstrin homology (PH) domain of AKT to disrupt binding of phosphatidylinositol-3,4,5-trisphosphate (PIP3), thereby downregulating AKT activity. Liposome pulldown assays coupled with fluorescence spectrometry were used to screen flavonoids for inhibition of the AKT PH-PIP3 interaction. Western blotting was used to determine the effects of the inhibitors on AKT activation in cancer cells, and in silico docking was used for structural analysis and optimization of inhibitor structure. Several flavonoids showing up to 50% inhibition of the AKT PH-PIP3 interaction decreased the level of AKT activation at the cellular level. In addition, the modified flavonoid showed increased inhibitory effects and the approach would be applied to develop anticancer drug candidates. In this study, we provide a rationale for targeting the lipidbinding domain of AKT, rather than the catalytic kinase domain, in anticancer drug development.
참고문헌 (34)
- Stahelin RV, "Lipid binding domains: more than simple lipid effectors", J. Lipid Res., 50, pp.S299~S304 (2009)[DOI]
- Hurley JH, "Subcellular targeting by membrane lipids", Curr. Opin. Cell Biol., 13, pp.146~152 (2001)[DOI]
- Park M-J, "SH2 domains serve as lipid-binding modules for pTyrsignaling proteins", Mol. Cell, 62, pp.7~20 (2016)[DOI]
- Vivanco I, "The phosphatidylinositol 3-kinase-AKT pathway in human cancer", Nat. Rev. Cancer, 2, pp.489~501 (2002)[DOI]
- Maehama T, "PTEN: a tumour suppressor that functions as a phospholipid phosphatase", Trends Cell Biol., 9, pp.125~128 (1999)[DOI]
- Osaki M, "PI3K-Akt pathway: its functions and alterations in human cancer", Apoptosis, 9, pp.667~676 (2004)[DOI]
- Vanhaesebroeck B, "The PI3K-PDK1 connection: more than just a road to PKB", Biochem. J., 346, pp.561~576 (2000)
- Hemmings BA, "Pi3k-pkb", akt pathway, 2012, pp.4, a011189~
- Luo J, "Targeting the PI3KAkt pathway in human cancer: rationale and promise", Cancer Cell, 4, pp.257~262 (2003)[DOI]
- Vara JAF, "PI3K", Akt signalling pathway and cancer, 2004, pp.30, 193~204
- Matei D, "Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor <TEX>${\alpha}$<", TEX> and Akt inactivation, 2004, pp.10, 681~690
- Bellacosa A, "Akt activation by growth factors is a multiple-step process: the role of the PH domain", Oncogene, 17 (1998)
- Manning BD, "AKT", PKB signaling: navigating downstream, 2007, pp.129, 1261~1274
- Miao B, "Small molecule inhibition of phosphatidylinositol- 3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains", Proc. Natl. Acad. Sci., 107, pp.20126~20131 (2010)[DOI]
- Yip WK, "Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma", Oncol. Rep., 19, pp.319~328 (2008)
- Okuzumi T, "Inhibitor hijacking of Akt activation", Nat. Chem. Biol., 5, pp.484~493 (2009)[DOI]
- Kang Y, "Inhibitory potential of flavonoids on PtdIns (3, 4, 5) P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain", Bioorg. Med. Chem. Lett., 27, pp.420~426 (2017)[DOI]
- Milburn CC, "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change", Biochem. J., 375, pp.531~538 (2003)[DOI]
- Wallace AC, "LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions", Protein Eng. Design Select., 8, pp.127~134 (1995)[DOI]
- Yoon H, "Design, synthesis and inhibitory activities of naringenin derivatives on human colon cancer cells", Bioorg. Med. Chem. Lett., 23, pp.232~238 (2013)[DOI]
- Jez JM, "Structure and mechanism of the evolutionarily unique plant enzyme chalcone isomerase", Nat. Struct. Biol., 7, pp.786~791 (2000)[DOI]
- Pettersen EF, "UCSF Chimera-a visualization system for exploratory research and analysis", J. Comp. Chem., 25, pp.1605~1612 (2004)[DOI]
- Miao B, "Inhibition of cell migration by PITENINs: the role of ARF6", Oncogene, 31, pp.4317~4332 (2012)[DOI]
- Ringel MD, "Overexpression and overactivation of Akt in thyroid carcinoma", Cancer Res., 61, pp.6105~6111 (2001)
- Li Y, "The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt", Mol. Cancer Therapeutics, 9, pp.113~125 (2010)
- Lin H, "Elevated phosphorylation and activation of PDK-1", AKT pathway in human breast cancer, 2005, pp.93, 1372~1381
- Suh Y, "Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells", Carcinogenesis, 31, pp.1424~1433 (2010)[DOI]
- Adhami VM, "Dietary flavonoid fisetin: a novel dual inhibitor of PI3K", Akt and mTOR for prostate cancer management, 2012, pp.84, 1277~1281
- Lee MS, "Antiprostate cancer potential of gossypetin via inducing apoptotic and autophagic cell death", Mol. Carcinogenesis (2017)
- Kim YH, "TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation", J. Cell. Biochem., 100, pp.998~1009 (2007)[DOI]
- Brownson DM, "Flavonoid effects relevant to cancer", J. Nutrit., 132, pp.3482S~3489S (2002)
- Lien EC, "PI3K signaling in cancer: beyond AKT", Curr. Opin. Cell Biol., 45, pp.62~71 (2017)[DOI]
- Zlotorynski E, "Non-coding RNA: The cancer link (RNA) between PIP3 and AKT", Nat. Rev. Mol. Cell Biol., 18, pp.212~213 (2017)
- Ebner M, "PI (3, 4, 5) P 3 Engagement restricts Akt activity to cellular membranes", Mol. Cell, 65, pp.416~431 (2017)[DOI]